Total lymphoid irradiation (TLI) has been used to control renal and cardiac allograft rejection. Data evaluating TLI in bronchiolitis obliterans syndrome (BOS), the physiological manifestation of chronic lung allograft rejection, is very limited. We present our single center experience of the safety and efficacy of TLI in controlling progressive BOS in a retrospective study. Over 12 years, 37 lung recipients (16 M:21 F) who had undergone 13 single; 12 bilateral and 12 heart-lung transplants were treated with TLI for progressive BOS. Grades at time TLI given were BOS 1 (n = 7) BOS 2 (n = 14) BOS 3 (n = 16). Twenty-seven (73%) completed >8/10 fractions, 10 (27%) failed to complete TLI. Two died from advanced BOS during treatment, 8 stopped early (range 3-7 fractions) due to marrow suppression (6) or infection (2). In the 27 recipients who completed >8/10 fractions, decline in FEV1 was 122.7 mls/month pre-TLI and 25.1 mls/month post-TLI, p = 0.0004, mean (95% CI) change in rate of decline was 97.5 (48.2-146.7) mls/month. TLI significantly reduces the rate of decline in graft function associated with BOS. TLI is well tolerated and associated with few serious complications and is an appropriate immunosuppressive approach in progressive BOS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-6143.2004.00709.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an Enabled Drug Discovery Platform.
J Med Chem
December 2024
Schrödinger Inc., New York, New York 10036, United States.
Despite the success of first, second, and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer with classical EGFR mutations (L858R or Exon 19 deletions), disease progression occurs due to the acquisition of T790M and C797S resistance. Herein, we report a physics-based computationally driven lead identification approach that identified structurally unique imidazo[3.2-]pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations bearing both T790M and C797S.
View Article and Find Full Text PDFChanges in Cerebral Hemodynamics and Progression of Subclinical Vascular Brain Disease: A Population-Based Cohort Study.
Stroke
January 2025
Department of Epidemiology (D.B., F.J.W., A.H., M.A.I., M.W.V.), Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Article Synopsis
- Cerebral hypoperfusion, or reduced blood flow to the brain, may lead to brain injury and degeneration, but its long-term effects, especially in healthier older adults, are not well understood.
- This study tracked 3,623 healthy older adults over 11 years using brain scans to measure cerebral blood flow (CBF) and cerebrovascular resistance, aiming to examine changes in subclinical brain disease markers like white matter hyperintensities.
- Results showed that significant changes in CBF and increased cerebrovascular resistance were linked to a higher risk of progression in white matter hyperintensities, suggesting that monitoring blood flow can help identify potential brain health issues in older adults.
High-dimensional tissue profiling of immune cell responses in chronic lung allograft dysfunction.
J Heart Lung Transplant
November 2024
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Institute of Transplantation, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
Article Synopsis
- The study investigates the immune mechanisms behind chronic lung allograft dysfunction (CLAD), which hampers long-term survival after lung transplants, using advanced tissue imaging techniques.
- Researchers analyzed lung tissue from 23 transplant recipients, identifying differences in immune cell populations associated with CLAD versus non-CLAD conditions.
- Key findings show that specific immune cells, like cytotoxic T cells and γδ T cells, expand in CLAD, highlighting unique characteristics in different CLAD phenotypes and offering new insights into how fibrosis progresses in these conditions.*
Induction of Cure in Early Arthritis (I CEA): study protocol for an investigator-initiated randomized single-blind clinical trial with open-label extension to compare three treatment strategies in patients with newly diagnosed undifferentiated arthritis.
Trials
November 2024
Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Background: Undifferentiated arthritis (UA) is a term used to describe patients with inflammatory arthritis that has not differentiated into a specific rheumatic disease. UA may be a pre-stage of rheumatoid arthritis (RA) or another inflammatory disease or remain undifferentiated, but a substantial proportion of patients may also achieve spontaneous remission. As UA may be an early presentation of RA, rheumatologists often start methotrexate (or another csDMARD) as early as possible.
View Article and Find Full Text PDFHypoxia-Induced Differences in the Expression of Pyruvate Dehydrogenase Kinase 1-Related Factors in the Renal Tissues and Renal Interstitial Fibroblast-like Cells of Yak (Bos Grunniens).
Animals (Basel)
October 2024
Engineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Northwest Minzu University, Lanzhou 730030, China.
Hypoxia is one of the factors severely affect renal function, and, in severe cases, it can lead to renal fibrosis. Although much progress has been made in identifying the molecular mediators of fibrosis, the mechanisms that govern renal fibrosis remain unclear, and there have been no effective therapeutic anti-fibrotic strategies to date. Mammals exposed to low oxygen in the plateau environment for a long time are prone to high-altitude disease, while yaks have been living in the plateau for generations do not develop kidney fibrosis caused by low oxygen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!